Faron Pharmaceuticals Oy (LSE:FARN)

£ 0.985 0.005 (0.51%) Market Cap: 85.38 Mil Enterprise Value: 90.65 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Full Year 2023 Faron Pharmaceuticals Oy Earnings Call Transcript
Mar 13, 2024

£1.2 (+7.41%)

Earnings
Faron Pharmaceuticals Oy at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Faron Pharmaceuticals Oy Recent BEXMAB results and future outlook Event Transcript
Oct 11, 2023
Half Year 2023 Faron Pharmaceuticals Oy Earnings Call Transcript
Aug 29, 2023

£2.49 (+11.11%)

Earnings
Faron Pharmaceuticals Oy at Canaccord Genuity Growth Conference Transcript
Aug 10, 2023
Faron Pharmaceuticals Oy BEXMAB Study Update Transcript
Jul 19, 2023
Full Year 2022 Faron Pharmaceuticals Oy Earnings Call Transcript
Mar 02, 2023

£2.74 (+1.54%)

Earnings
Half Year 2022 Faron Pharmaceuticals Oy Earnings Call Transcript
Aug 25, 2022

£1.52 (-5.19%)

Earnings
Full Year 2021 Faron Pharmaceuticals Oy Earnings Call Transcript
Mar 25, 2022

£1.95 (+0.43%)

Earnings
Half Year 2021 Faron Pharmaceuticals Oy Earnings Call Transcript
Aug 26, 2021

£3.82 (-5.15%)

Earnings

Faron Pharmaceuticals Oy BEXMAB Study Update Transcript

Jul 19, 2023 / 12:30PM GMT

Release Date Price: £2.23 (+5.93%)

Transcript

Operator

Greetings and welcome to the Faron Pharmaceuticals' BEXMAB study update. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the call over to your host, Dan Ferry of LifeSci Advisors. Thank you. You may begin.

Dan Ferry

Lifesci Advisors LLC - IR

Thank you, operator. Good morning, everyone, and welcome to the Faron Pharmaceuticals conference call to discuss the positive BEXMAB data from Phase 1/2 trial cohorts in patients with relapsed refractory AML and MDS and next steps for the program. A press release highlighting these updates is available on the Investors page of the corporate website at faron.com. We will be conducting a question-and-answer session at the end of the call.

Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements regarding our regulatory, product development, and commercialization plans, and research activities. These statements are subject to risks and uncertainties that could cause actual results to

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.